MentalHealthDaily

Transcranial Temporal Interference Stimulation (tTIS) May Improve Parkinson’s Motor Symptoms

by GLOOM

Photoreal illustration of two interfering electric fields converging at deep brain regions, conveying non-invasive deep stimulation in Parkinson's.

Deep brain stimulation works for Parkinson’s, but it requires implanted electrodes. A 2026 randomized crossover trial by Stalter and colleagues tested whether transcranial temporal interference stimulation — a non-invasive technique designed to reach deep targets without exciting overlying cortex — can move the needle on motor symptoms when aimed at the putamen.1 Research Highlights Transcranial …

Plasma p-tau217 Blood Test Predicts Alzheimer’s Risk 1.5x Stronger in APOE-e4

by GLOOM

Photoreal illustration representing a blood biomarker test for Alzheimer's disease with imagery of blood vials, neurons, and APOE genetic motifs.

Until recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive result depends substantially on APOE genotype.1 Research Highlights Plasma p-tau217 is a blood biomarker that rises years before Alzheimer’s symptoms. The 2024 Alzheimer’s Association revised criteria …

tVNS Alters Effort and Reward Decisions in Severe Depression

by GLOOM

Photoreal illustration of an ear-clip vagus nerve stimulation electrode, with neural pathway motifs representing reward-effort circuits.

An ear-clip that modulates mood by stimulating the vagus nerve has obvious appeal — but the evidence base for non-invasive tVNS in depression has been mixed for a decade. A 2026 cross-over RCT by Forbes et al. sharpens what specifically tVNS does well.1 Research Highlights Transcutaneous vagus nerve stimulation (tVNS) is a non-invasive ear-electrode version …

Lewy Body Dementia Cognitive Fluctuations Affect 75-90% of Patients

by GLOOM

Photoreal illustration of fluctuating brain activity overlay on an older adult, conveying alertness variability characteristic of DLB.

Cognitive fluctuations are a defining feature of dementia with Lewy bodies (DLB), helping distinguish it from Alzheimer’s disease — but they remain notoriously difficult to characterize and measure. A 2026 review by Mahajan and colleagues maps the neurobiology, measurement, and clinical implications of fluctuations across the Lewy body spectrum.1 Research Highlights Cognitive fluctuations are episodes …

Psychedelic Media Coverage Outpaced Evidence (2017–2024)

by GLOOM

Photoreal illustration of newspaper headlines and scientific journals about psychedelic treatments, conveying media-evidence calibration.

Psychedelic-assisted therapy has been one of the most-covered mental-health stories of the past decade. A 2026 quantitative analysis by Evers and colleagues maps how media enthusiasm grew, peaked, and partially pulled back across major U.S. outlets — and how the coverage related to the actual evidence base for depression and PTSD.1 Research Highlights Psychedelic clinical …

Naltrexone/Bupropion Reduced Food Intake in Binge-Eating Lab Study

by GLOOM

Photoreal illustration of brain reward circuitry overlaid on imagery of palatable food, conveying pharmacological reduction of consummatory reward.

Lisdexamfetamine remains the only FDA-approved medication for binge-eating disorder — a serious condition affecting roughly 1.2% of adults. A 2026 human laboratory study by McKee and colleagues tests whether naltrexone/bupropion, already approved for obesity, reduces the food-reward mechanisms that drive binge episodes.1 Research Highlights Binge-eating disorder (BED) is the most common eating disorder in the …

Inflammation Tracks White-Matter MRI in Aging Adults

by GLOOM

Chronic low-grade inflammation rises with age, and a growing body of work asks whether peripheral inflammatory markers in blood track subtle changes in brain white-matter microstructure on MRI. A 2026 preprint from the Healthy Minds for Life cohort by Mishra and colleagues at Johns Hopkins examined 457 dementia-free adults aged 50–79 and found that higher …